Mylan NV (MYL)

41.60
NASDAQ : Health Care
Prev Close 41.60
Day Low/High 0.00 / 0.00
52 Wk Low/High 33.60 / 50.40
Avg Volume 5.46M
Exchange NASDAQ
Shares Outstanding 535.50M
Market Cap 22.33B
EPS 1.80
P/E Ratio 45.33
Div & Yield N.A. (N.A)

Latest News

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

The settlement provides Mylan with global licenses for its trastuzumab product.

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

A firestorm in Washington has created a fire sale for shares of this undervalued stock.

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'

Mylan's Governance May Be the Root of Its Problems

Mylan's Governance May Be the Root of Its Problems

The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Forty states have now sued the companies.

Dow Adds 300 Points as Stocks Enjoy Best Day of 2017 on Optimism Over U.S. Economy

Dow Adds 300 Points as Stocks Enjoy Best Day of 2017 on Optimism Over U.S. Economy

Stocks enjoy their best gains of the year as investors rejoice over the Federal Reserve's apparent faith in the U.S. economy.

Stocks Hold Big Gains, Dow Hits 21,000 on Optimism Over U.S. Economy

Stocks Hold Big Gains, Dow Hits 21,000 on Optimism Over U.S. Economy

Stocks hold big gains through Wednesday morning, trading at all-time highs, as investors rejoice over the Federal Reserve's apparent faith in the U.S. economy.

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.

Stock Futures Higher as Chances Rise of a Rate Hike in March

Stock Futures Higher as Chances Rise of a Rate Hike in March

Stock futures suggest Wall Street would get back to its record-breaking ways on Wednesday as chances rose of a return to normal U.S. monetary policy sooner rather than later.

Mylan Stock Spikes on Earnings Beat

Mylan Stock Spikes on Earnings Beat

Mylan topped bottom line estimates by 15 cents.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

We Might See a Pullback in Bonds Sometime This Week

In one scenario, we crack these levels and then come back and retest on the pullback.

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Pegfilgrastim For Review

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Pegfilgrastim For Review

Second Successful BLA Filing of the Partnership in the U.S.

How Kaleo Pharma Prices Its EpiPen Competitor

How Kaleo Pharma Prices Its EpiPen Competitor

Kaleo's EpiPen compeitor the Auvi-Q was released today.

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Mylan Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Skyworks Solutions

Mylan Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Skyworks Solutions

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

CVS Remains Unsure About the Future of Obamacare, CEO Says

CVS Remains Unsure About the Future of Obamacare, CEO Says

The company had a mixed fourth quarter.

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.

Despite Settling Decade-Long Suit, Mylan Shares Fall

Despite Settling Decade-Long Suit, Mylan Shares Fall

Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.

There Is Nothing Generic About the Basing Action on Mylan

There Is Nothing Generic About the Basing Action on Mylan

Prices look set to test key resistance, and this time should see a breakout to the upside.